Mineralys Therapeutics Inc's Customers Performance

Name: Mineralys Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

MLYS

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


MLYS's Source of Revenues		• List of MLYS Customers

for the same period Mineralys Therapeutics Inc

• List of MLYS Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Mineralys Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Mineralys Therapeutics Inc Contracts

Breakthrough in Hypertension Treatment Mineralys Therapeutics Lorundrostat Shows Promising Results in Div...

Mineralys Therapeutics has unveiled pivotal data from their groundbreaking Phase 3 Launch-HTN trial, focusing on the novel aldosterone synthase inhibitor, lorundrostat. The presentation highlights significant achievements in the treatment of hypertension, particularly among participants with a high unmet medical need. This trial is not only a hallmark in therapeutic innovations for hypertension but also a beacon of hope for those struggling with uncontrolled or resistant forms of this pervasive condition. A Clarion Call for Novel InterventionsHypertension, often termed the silent killer, poses immeasurable risks due to its asymptomatic nature. It affects millions globally, often leading to severe complicatio...

Mineralys Therapeutics Reveals Promising Data for Lorundrostat at ESH 2025, Targets Future Engagements in Upcoming He...

Mineralys Therapeutics Unveils Groundbreaking Findings on Lorundrostat at ESH 2025 Amidst Conference Participation In a significant stride for hypertension treatment, Mineralys Therapeutics, Inc. (NASDAQ: MLYS) recently unveiled late-breaking data from their pivotal Launch-HTN trial of lorundrostat at the 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025). This innovative study is the largest of its kind involving an aldosterone synthase inhibitor, presenting compelling evidence of lorundrostat s efficacy in managing uncontrolled or resistant hypertension. Pivotal Trial HighlightsConducted in a real-world setting, the Launch-HTN trial enrolled over 1,000 participants diagnosed wi...

MLYS's Stock Performance relative to it's Customers

MLYS's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Mineralys Therapeutics Inc	2,486.75	0.00	-151.78	76
SUBTOTAL	0.00	0.00	0.00	-

Sources: Mineralys Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Mineralys Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Mineralys Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.